Boehringer's Blood Pressure Drug Cuts Down Cardiovascular Risks
Posted on: Tuesday, 1 April 2008, 12:00 CDT
Boehringer Ingelheim has reported that results of the landmark Ontarget trial have proved that the company's Micardis is as protective as ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke, and hospitalisation for congestive heart failure, in a broad cross-section of high-risk cardiovascular patients and with better tolerability.
These cardiovascular events occurred in 16.66% of patients receiving Micardis (telmisartan) versus 16.46% of patients receiving ramipril. The relative risk (ratio of the probability of the event occurring in the telmisartan group versus the ramipril group) was 1.01, with a 95% CI of 0.94 -1.09. The Ontarget data also show that telmisartan is associated with a higher treatment compliance.
In this trial the benefits of telmisartan were demonstrated in a large group (8,542) of high-risk patients who were already receiving standard care such as statins to lower cholesterol, antiplatelet therapy, beta blockers and other antihypertensives. Telmisartan treatment led to fewer discontinuations than treatment with ramipril, a widely used angiotensin converting enzyme inhibitor (ACE) inhibitor. Although patients with an ACE inhibitor intolerance had been excluded from the trial, 360 (4.2%) patients in the ramipril treatment arm stopped their treatment because they experienced cough, a common ACE inhibitor side effect, versus only 93 (1.1%) patients in the telmisartan arm.
Salim Yusuf, lead investigator of the Ontarget program, said: "The Ontarget trial shows that telmisartan is a well-tolerated treatment in high-risk cardiovascular patients that is as effective as ramipril in preventing heart attacks, stroke and hospitalizations for heart failure and deaths. The Ontarget results have important implications for the management of patients with cardiovascular diseases."
Source: Datamonitor
Related Articles
- AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
- Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective As Ramipril, With Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
- Vion Initiates Pivotal Phase II Trial of Single Agent Cloretazine(R) in Elderly Patients With De Novo Poor-Risk Acute Myelogenous Leukemia
- Cardiovascular Risks Fell After Patients Quit Vioxx, Data Show
- Animi-3(R) Clinical Trial for Cardiovascular Risk Reduction and Cognition Begins With Leading Medical Researcher From Tufts University
- Atherogenic Lipid Profile and Cardiovascular Risk Factors in HIV- Infected Patients (Ntar Study)
- First Melanoma Patients Complete Treatment in Provectus Phase 1 Clinical Trial of PV-10
- The Effect of Irbesartan in Reducing Cardiovascular Risk in Hypertensive Type 2 Diabetic Patients: an Observational Study in 16 600 Patients in Primary Care
- The ORLIstat and CArdiovascular Risk Profile in Patients With Metabolic Syndrome and Type 2 DIAbetes (ORLICARDIA) Study
- Study Shows Impact of Coreg(R) (Carvedilol) on Cardiovascular Risk Factors in Patients With Diabetes and Hypertension
 |
 |
User Comments (0)
RSS Feeds